<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Unipolar major depression with psychotic features: Acute treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Unipolar major depression with psychotic features: Acute treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Unipolar major depression with psychotic features: Acute treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anthony J Rothschild, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 24, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H14443905">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unipolar major depression with psychotic features is a severe subtype of unipolar major depression (major depressive disorder) [
         <a href="#rid1">
          1
         </a>
         ]. The psychotic symptoms are delusions and/or hallucinations that are frequently consistent with depressive themes of guilt and worthlessness [
         <a href="#rid2">
          2
         </a>
         ]. Psychotic depression and nonpsychotic depression differ in their diagnosis, treatment, and prognosis.
        </p>
        <p>
         This topic reviews the acute treatment of unipolar major depression with psychotic features. Maintenance treatment and prognosis are discussed elsewhere, as are the epidemiology, pathogenesis, clinical features, assessment, and diagnosis of psychotic depression. (See
         <a class="medical medical_review" href="/z/d/html/16596.html" rel="external">
          "Unipolar major depression with psychotic features: Maintenance treatment and course of illness"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">
          "Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1060271">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unipolar major depression with psychotic features is characterized by an episode of unipolar major depression that includes delusions and/or hallucinations [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Unipolar major depression (major depressive disorder) is diagnosed in patients who have suffered at least one major depressive episode  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 1
         </a>
         ) and have no history of mania  (
         <a class="graphic graphic_table graphicRef91106" href="/z/d/graphic/91106.html" rel="external">
          table 2
         </a>
         ) or hypomania  (
         <a class="graphic graphic_table graphicRef91107" href="/z/d/graphic/91107.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. A major depressive episode is a two week or longer period with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, guilt, and recurrent thoughts about death or suicide. The clinical presentation and diagnosis of unipolar major depression are discussed further elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis"
         </a>
         .)
        </p>
        <p>
         The primary distinction between unipolar major depression with psychotic features and unipolar major depression without psychotic features is that psychotic depression includes [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delusions – False, fixed beliefs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hallucinations – False sensory perceptions
        </p>
        <p>
        </p>
        <p>
         The clinical features, diagnosis, and differential diagnosis of unipolar major depression with psychotic features are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">
          "Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14442291">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4939142">
         <span class="h2">
          General principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most episodes of unipolar major depression are treated by internists [
         <a href="#rid3">
          3
         </a>
         ]. However, unipolar psychotic depression is more difficult to treat and most patients are referred to psychiatrists [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The goal of treating unipolar psychotic depression is remission, which is defined as resolution of both the psychotic symptoms (delusions or hallucinations) and depressive symptoms. Patients whose psychosis resolves and whose depression improves to the point that only one or two symptoms of mild intensity persist are also regarded as remitted. For patients who do not achieve remission, a reasonable goal is response, which is defined as stabilization of the patient’s safety and substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms.
        </p>
        <p>
         Depressive and psychotic symptoms should be monitored regularly with clinical interviews that pay particular attention to:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suicidal ideation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Suicide plans
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychotic symptoms that place the patient at imminent risk of coming to harm (eg, auditory hallucinations commanding the patient to kill themselves)
        </p>
        <p>
        </p>
        <p>
         The frequency of assessment generally ranges from daily to monthly, depending upon the severity of persistent symptoms. Hospitalized patients are monitored daily, and patients with active suicidal ideation, a specific plan, and intent to kill themselves may require constant observation. Outpatients who have not achieved substantial improvement in the number, intensity, and frequency of psychotic and mood symptoms are generally seen weekly; those who have improved substantially may be seen every two to four weeks until they remit.
        </p>
        <p>
         Patients with psychotic depression can also be monitored with the
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fpsychoticdepressionassessmentscale.com%2F&amp;token=UwtSYlpnHcrWIMOIN28XfUMUAplDHbG%2BfZNbjeYNTFg2TgwknhJobqUDGeKTsSRA%2Ba%2B35AEuUutb%2BfgAT9CFkQ%3D%3D&amp;TOPIC_ID=16546" target="_blank">
          Psychotic Depression Assessment Scale
         </a>
         , but this is not standard clinical practice. The scale is a clinically valid, empirically tested, 11-item, clinician-administered instrument [
         <a href="#rid5">
          5-9
         </a>
         ]. The scale consists of the six-item melancholia subscale of the Hamilton Rating Scale for Depression [
         <a href="#rid10">
          10
         </a>
         ] and five psychosis items from the Brief Psychiatric Rating Scale [
         <a href="#rid11">
          11
         </a>
         ]. The use of scales to monitor symptoms of depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">
          "Using scales to monitor symptoms and treat depression (measurement based care)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13923869">
         <span class="h2">
          First line
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest treating unipolar major depression with psychotic features with either of the following [
         <a href="#rid12">
          12,13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antidepressant plus an antipsychotic, or
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Electroconvulsive therapy (ECT)
        </p>
        <p>
        </p>
        <p>
         This approach is consistent with treatment guidelines from the American Psychiatric Association [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H57129843">
         <span class="h3">
          Choosing a treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         A review of low quality studies found that ECT and the combination of an antidepressant plus an antipsychotic each improved symptoms of unipolar psychotic depression to a similar degree [
         <a href="#rid14">
          14
         </a>
         ]; thus, the initial choice for treating unipolar psychotic depression is based upon other factors. Combination pharmacotherapy is generally selected as initial treatment because it is easier to administer, more widely available, and more acceptable to patients compared with ECT [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         However, because ECT is generally faster than pharmacotherapy, ECT should be used initially for patients with severe psychosis that places the patient at imminent risk of coming to harm (eg, the patient is distracted by hallucinations to the point of unwittingly walking into moving traffic), severe suicidality (eg, active suicidal ideation with a plan and intent), or malnutrition secondary to food refusal. Initial treatment with ECT is also reasonable for patients who prefer it or responded well to it during prior episodes of unipolar psychotic depression. Another factor to consider is cost [
         <a href="#rid16">
          16-18
         </a>
         ].
        </p>
        <p>
         Studies showing that the combination of an antidepressant and an antipsychotic is comparable with ECT for unipolar psychotic depression were generally open-label, and often included nonrandom assignment or consisted of retrospective chart reviews [
         <a href="#rid19">
          19
         </a>
         ]. Patients with heterogeneous diagnoses were included, and different types of ECT (bilateral and unilateral) were compared with different combinations of tricyclic antidepressants and first-generation antipsychotics prescribed at varying doses for different lengths of time [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13924267">
         <span class="h3">
          Antidepressant plus antipsychotic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon randomized trials [
         <a href="#rid21">
          21-25
         </a>
         ], we prefer the combination of an antidepressant and an antipsychotic rather than antidepressant monotherapy or antipsychotic monotherapy for unipolar psychotic depression. This results in better patient adherence and outcomes [
         <a href="#rid26">
          26
         </a>
         ] and is consistent with multiple practice guidelines [
         <a href="#rid12">
          12,13,27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H85451847">
         <span class="h4">
          Choosing a combination
         </span>
         <span class="headingEndMark">
          —
         </span>
         We favor treating unipolar psychotic depression with antidepressant/antipsychotic combinations that have demonstrated efficacy in randomized trials. The following combinations have shown beneficial effects compared with antidepressant monotherapy, antipsychotic monotherapy, or placebo in well-designed, sufficiently large trials:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          Sertraline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         [
         <a href="#rid21">
          21
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          Fluoxetine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         [
         <a href="#rid22">
          22
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          Venlafaxine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         [
         <a href="#rid23">
          23
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          Amitriptyline
         </a>
         plus
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          Amitriptyline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         [
         <a href="#rid25">
          25
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         None of the combinations have been compared in head-to-head trials.
        </p>
        <p>
         However, it is reasonable to initially treat psychotic depression with a combination that has not been studied in randomized trials. Many alternative combinations are available from existing antidepressants (selective serotonin reuptake inhibitors [SSRIs], tricyclics, serotonin-norepinephrine reuptake inhibitors [SNRIs], and antidepressants with a unique mechanism of action) and antipsychotics (first- and second-generation).
        </p>
        <p>
         We typically use
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         as initial pharmacotherapy for unipolar psychotic depression because this combination has been studied in the most patients. Based upon the randomized trial that established the efficacy of this combination, we typically use the following dose schedule [
         <a href="#rid21">
          21
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Initial dose of
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         50 mg/day plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         5 mg/day
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         by 50 mg/day and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         by 5 mg/day every three days as tolerated
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Attempt to reach
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         dose of at least 100 mg/day and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         10 mg/day within seven days of starting treatment
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Minimum target doses are
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         150 mg/day and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         15 mg/day, usually beginning no later than week two
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maximum target doses are
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         200 mg/day and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         20 mg/day, usually beginning no later than week three
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Allow slower titration or temporary dose reductions of one or both medications if side effects occur; however, subsequent dose increases should be attempted
        </p>
        <p>
        </p>
        <p>
         Older adult patients can initially receive
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         25 mg/day and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         2.5 mg/day. The dose is then increased by the same amount every three to five days to a minimum target dose of sertraline 150 mg/day and olanzapine 15 mg/day, and a maximum target dose of sertraline 200 mg/day and olanzapine 20 mg/day.
        </p>
        <p>
         Three percent of patients receiving
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         withdrew from the trial because of intolerable side effects [
         <a href="#rid21">
          21
         </a>
         ]. Adverse effects of the combination included:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight gain of at least 2.7 kg (54 percent of patients)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation (29 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Orthostasis (16 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One or more falls (16 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Significant increases in serum cholesterol, triglyceride, and glucose concentrations from baseline to study termination
        </p>
        <p>
        </p>
        <p>
         Additional information about the side effects of
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Side effects'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects", section on 'Adverse effects'
         </a>
         .)
        </p>
        <p>
         The combination of an antidepressant plus a phenothiazine antipsychotic (eg,
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         , mesoridazine,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         ) may cause adverse drug interactions. In a case control study, the medication history was examined in 1814 cases of sudden cardiac death and 1171 controls who survived an acute myocardial infarction; the analyses controlled for risk factors such as hypertension, diabetes, and hypercholesterolemia [
         <a href="#rid29">
          29
         </a>
         ]. Compared with controls, cases were significantly more likely to have been treated with phenothiazines plus any antidepressant (odds ratio 9.6, 95% CI 1.2-80.8).
        </p>
        <p>
         Specific interactions between antidepressants and antipsychotics may be determined using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included in UpToDate.
        </p>
        <p class="headingAnchor" id="H230508">
         <span class="h4">
          Duration of therapy and switching drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Following protocols used in randomized trials, unipolar psychotic depression is treated with an antidepressant plus an antipsychotic at minimum target doses or higher for four to eight weeks before determining whether the combination is effective [
         <a href="#rid22">
          22-25
         </a>
         ]. Intervening adverse effects may necessitate discontinuing one or both drugs sooner than four weeks.
        </p>
        <p>
         If patients do not respond to or tolerate
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , we suggest using another combination with demonstrated efficacy in a randomized trial, including
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus olanzapine,
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         plus
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , or amitriptyline plus
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         . The new combination is started and titrated up with the goal of reaching minimum target doses within two weeks, while the failed combination is concurrently tapered and discontinued over one to two weeks.
        </p>
        <p>
         For patients who do not respond to or tolerate
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         ,
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         , or
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         , it is reasonable to use another SSRI, SNRI, tricyclic, or an antidepressant with a unique mechanism of action. Similarly, if patients do not respond to or tolerate
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         , it is reasonable to use another second- or first-generation antipsychotic, except for
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         , which can cause agranulocytosis. Most authorities and clinicians switch antidepressant classes when starting a new course of combination pharmacotherapy. Antidepressants and antipsychotics are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1713.html" rel="external">
          "Serotonin-norepinephrine reuptake inhibitors: Pharmacology, administration, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14773.html" rel="external">
          "First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4459881">
         <span class="h4">
          Evidence of efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data suggest that for individuals with unipolar psychotic depression, the combination of an antidepressant and an antipsychotic may be more effective than antidepressant monotherapy, antipsychotic monotherapy, or placebo [
         <a href="#rid30">
          30-32
         </a>
         ]. However, the efficacy of antidepressant monotherapy and antipsychotic monotherapy appears to be comparable with placebo [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
         As examples, in a meta-analysis of randomized trials, the combination of antidepressant and antipsychotic monotherapies led to a greater rate of response (defined as &gt;50 percent reduction in baseline symptoms) than antipsychotic monotherapy (n = 447; relative risk 1.8, 95% CI 1.4-2.4), antidepressant monotherapy (n = 245; relative risk 1.4, 95% CI 1.1-1.8), or placebo (n = 148; relative risk 1.9, 95% CI 1.2-2.8) [
         <a href="#rid32">
          32
         </a>
         ]. Discontinuation for any reason was comparable for the groups. However, in a different meta-analysis, despite similar rates of all-cause discontinuation and reported side effects, sedation was greater with combination therapy than with antidepressant monotherapy (relative risk 2.8, 95% CI 1.1-6.8) [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In an analysis of two of the trials in the meta-analysis, treatment with either antipsychotic monotherapy (
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         ) or antidepressant monotherapy (
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         ) led to response rates comparable with those in the placebo groups (n = 201; relative risk 1.13, 95% CI 0.7-1.7 and n = 27; relative risk 8.4, 95% CI 0.5-142.2, respectively) [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Evidence from this meta-analysis was deemed low certainty because of risk of bias and heterogeneity across studies.
        </p>
        <p class="headingAnchor" id="H13924275">
         <span class="h3">
          Electroconvulsive therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         ECT uses two scalp electrodes to administer an electric current to anesthetized patients and induce a tonic-clonic seizure. Initial treatment for most patients with unipolar psychotic depression consists of an antidepressant plus an antipsychotic. However, because ECT is generally faster than pharmacotherapy, clinicians should use ECT initially for patients with:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychosis that places the patient at imminent risk of coming to harm (eg, psychotic symptoms prevent the patient from attending to basic needs)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severe suicidality (eg, active suicidal ideation with a plan and intent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malnutrition secondary to food refusal
        </p>
        <p>
        </p>
        <p>
         Patients who responded well to ECT during prior episodes of unipolar psychotic depression are also good candidates for initial treatment with ECT.
        </p>
        <p>
         Based upon meta-analyses of randomized trials, the efficacy of ECT for treating unipolar major depression with or without psychotic features is well established [
         <a href="#rid12">
          12,13,34-37
         </a>
         ], and a review found that response to ECT appears to be better in psychotic depression than nonpsychotic depression [
         <a href="#rid34">
          34
         </a>
         ]. As an example, a prospective observational study included patients with unipolar psychotic depression (n = 77) or unipolar nonpsychotic depression (n = 176), who received bilateral ECT three times per week, and found that remission occurred in more psychotic patients than nonpsychotic patients (83 versus 71 percent) [
         <a href="#rid38">
          38
         </a>
         ]. In a retrospective study that included severely depressed patients treated with ECT (n = 627), response occurred in more psychotic patients than nonpsychotic patients (89 versus 82 percent) [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         ECT is generally safe and there are no absolute contraindications, even in patients whose general medical status is compromised [
         <a href="#rid37">
          37
         </a>
         ]. However, safety concerns regarding ECT necessitate preprocedure medical consultation. Adverse effects include cardiopulmonary events, aspiration pneumonia, fractures, dental and tongue injuries, headache, nausea, and cognitive impairment. Medical consultation prior to ECT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4817.html" rel="external">
          "Medical evaluation for electroconvulsive therapy"
         </a>
         .)
        </p>
        <p>
         Electrode placement and other aspects of ECT technique for treating unipolar psychotic depression have not been standardized. Thus, ECT is typically administered with the same technique used for other indications and is generally given three times per week on alternating days. Most patients, regardless of indication, remit with 6 to 12 treatments, but some patients may require 20 or more. Additional information about ECT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1709.html" rel="external">
          "Overview of electroconvulsive therapy (ECT) for adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1711.html" rel="external">
          "Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy (ECT)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1712.html" rel="external">
          "Technique for performing electroconvulsive therapy (ECT) in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13925748">
         <span class="h2">
          Resistant patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial treatment of unipolar psychotic depression may fail to stabilize the patient’s safety and substantially improve the number, intensity, and frequency of psychotic and mood symptoms. Patients resistant to one or two courses of an antidepressant/antipsychotic combination as initial treatment should receive ECT [
         <a href="#rid40">
          40
         </a>
         ]. Conversely, patients who initially receive an unsuccessful course of ECT should receive combination pharmacotherapy. ECT and choosing a pharmacotherapy combination are discussed separately. (See
         <a class="local">
          'Electroconvulsive therapy'
         </a>
         above and
         <a class="local">
          'Choosing a combination'
         </a>
         above.)
        </p>
        <p>
         For patients who do not respond to combination pharmacotherapy and who decline or do not have access to ECT, adding both
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         plus a specific type of psychotherapy may possibly improve outcomes; however, there is little evidence to support these adjunctive treatments. Other augmentation strategies have not been studied.
        </p>
        <p class="headingAnchor" id="H13926644">
         <span class="h3">
          Lithium
         </span>
         <span class="headingEndMark">
          —
         </span>
         Case reports describe patients with unipolar psychotic depression who initially did not respond to an antidepressant plus an antipsychotic, but subsequently improved with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         augmentation [
         <a href="#rid41">
          41-43
         </a>
         ]. Lithium is added after four to eight weeks of unsuccessful treatment with an antidepressant plus an antipsychotic, at a dose sufficient to achieve a 12-hour serum trough level of 0.5 to 1.0 mEq/L. At least two to four weeks at therapeutic levels is necessary to determine whether lithium augmentation is beneficial.
        </p>
        <p>
         Adjunctive treatment with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         for unipolar major depression without psychotic features is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/13506.html" rel="external">
          "Unipolar depression in adults: Treatment with lithium"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14442383">
         <span class="h3">
          Psychotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Psychotherapies studied for unipolar major depression with psychotic features include acceptance and commitment therapy, which teaches patients to increase their acceptance of unavoidable distress, to simply notice their psychotic symptoms without considering them as either true or false, and to identify and work toward personally valued goals [
         <a href="#rid44">
          44,45
         </a>
         ]. An open-label randomized trial found that in 18 patients with unipolar psychotic depression, symptomatic improvement occurred in significantly more patients who received acceptance and commitment therapy (average three sessions) plus treatment as usual, compared with patients who received treatment as usual alone.
        </p>
        <p>
         Another therapy studied for psychotic depression is acceptance-based depression and psychosis therapy; this intervention combines elements of acceptance and commitment therapy with behavioral activation (which focuses upon reducing avoidance of activities) [
         <a href="#rid46">
          46
         </a>
         ]. An observational study of 14 patients with psychotic depression who were treated with acceptance-based depression and psychosis therapy for up to six months suggests that the therapy may possibly be beneficial.
        </p>
        <p class="headingAnchor" id="H4939053">
         <span class="h2">
          Refractory patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unipolar psychotic depression that does not respond to one or two courses of an antidepressant plus an antipsychotic, a course of ECT, and adjunctive
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         and acceptance and commitment therapy should be treated with additional trials of an antidepressant plus an antipsychotic. Most authorities and clinicians switch antidepressant classes when starting a new course of combination pharmacotherapy (eg, switch from an SSRI to either an SNRI or a tricyclic). Patients with chronic, unremitting moderate to severe symptoms may require close monitoring and supervision within a structured setting (eg, group home or hospital), depending upon the risk of imminent harm to self or others. Choosing a pharmacotherapy combination and switching drugs are discussed separately. (See
         <a class="local">
          'Choosing a combination'
         </a>
         above and
         <a class="local">
          'Duration of therapy and switching drugs'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H14442390">
         <span class="h2">
          Family support
         </span>
         <span class="headingEndMark">
          —
         </span>
         Family members should be involved in the care of patients with unipolar psychotic depression, and be educated about the signs and symptoms, treatment, and prognosis of the illness. The family can provide information about symptoms that the patient may not reveal and can encourage adherence to treatment. Family meetings for assessment and treatment of patients with major depression are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1710.html" rel="external">
          "Unipolar depression in adults: Family and couples therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H129863201">
         <span class="h1">
          TIME TO RECOVERY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Observational studies show that about 50 percent of patients with unipolar psychotic depression recover within two to three months, and the large majority of patients recover within 6 to 12 months:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A five-year observational study of 61 in- or outpatients with unipolar psychotic depression estimated that the median time to recovery from prospectively observed episodes was 10 weeks [
         <a href="#rid47">
          47
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A two-year, prospective observational study of 53 patients hospitalized for unipolar psychotic depression estimated that 50 percent recovered within nine weeks of admission, 75 percent within six months, and 94 percent within 24 months [
         <a href="#rid48">
          48,49
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A one-year, community survey of 92 patients with unipolar psychotic depression found that during prospective follow-up, recovery occurred in 81 percent [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         However, a few patients may remain ill for approximately 10 years or longer [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         The rate of recovery may be less in unipolar psychotic depression than nonpsychotic depression [
         <a href="#rid50">
          50,51
         </a>
         ]. In a community survey of 92 patients with unipolar psychotic depression and 532 patients with unipolar nonpsychotic depression, recovery during one year of prospective follow-up occurred in significantly fewer psychotic patients than nonpsychotic patients (81 versus 89 percent) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H129863208">
         <span class="h2">
          Functional recovery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Social and occupational impairment usually occurs in unipolar psychotic depression [
         <a href="#rid47">
          47,50
         </a>
         ]. We suggest that patients gradually resume their normal activities following remission of the mood episode. As an example, patients can return to work on a part-time schedule and incrementally increase the hours to full-time.
        </p>
        <p>
         Functional recovery often lags recovery from psychotic and depressive symptoms [
         <a href="#rid47">
          47,52
         </a>
         ]. A prospective, two-year observational study of 53 patients with unipolar psychotic depression found that functional recovery (occupational and residential status) occurred in 29 percent, whereas recovery from the mood episode occurred in 94 percent [
         <a href="#rid49">
          49
         </a>
         ]. Based upon clinical experience, a quick and full recovery of psychosocial functioning is more probable in patients aged 30 to 65 years with good pre-morbid functioning, a first lifetime episode of unipolar psychotic depression, or a good response to treatment.
        </p>
        <p class="headingAnchor" id="H698742333">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116503.html" rel="external">
          "Society guideline links: Depressive disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14442474">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unipolar major depression with psychotic features is characterized by delusions and/or hallucinations that accompany a two week or longer period with five or more of the following symptoms: depressed mood, loss of interest or pleasure in most activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, guilt, and recurrent thoughts about death or suicide. (See
         <a class="local">
          'Terminology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">
          "Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First-line acute treatment for unipolar major depression with psychotic features is either electroconvulsive therapy (ECT) or combination pharmacotherapy with an antidepressant and an antipsychotic. For patients with mild to moderate disease, we suggest initial treatment with combination pharmacotherapy rather than ECT (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Combination pharmacotherapy is generally easier to administer, more widely available, and more acceptable to patients compared with ECT. (See
         <a class="local">
          'First line'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We prefer
         <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">
          sertraline
         </a>
         plus
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         as initial pharmacotherapy for unipolar psychotic depression because this combination has been studied with the most patients in randomized trials. Reasonable alternatives include
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         plus olanzapine,
         <a class="drug drug_general" data-topicid="10042" href="/z/d/drug information/10042.html" rel="external">
          venlafaxine
         </a>
         plus
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8605" href="/z/d/drug information/8605.html" rel="external">
          amitriptyline
         </a>
         plus
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , or amitriptyline plus
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         . (See
         <a class="local">
          'Choosing a combination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with unipolar psychotic depression that includes severe psychosis or suicidality, or malnutrition secondary to food refusal, we suggest initial treatment with ECT rather than combination pharmacotherapy (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). In addition, initial treatment with ECT is reasonable for patients who prefer it or responded well to it during prior episodes of unipolar psychotic depression. (See
         <a class="local">
          'First line'
         </a>
         above and
         <a class="local">
          'Electroconvulsive therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with unipolar psychotic depression who do not respond adequately to one or two courses of combination pharmacotherapy should receive ECT. Conversely, patients initially treated with an unsuccessful course of ECT should receive combination pharmacotherapy. (See
         <a class="local">
          'Resistant patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Approximately 50 percent of patients with unipolar psychotic depression recover within two to three months and the large majority of patients recover within 6 to 12 months. (See
         <a class="local">
          'Time to recovery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Social and occupational impairment usually occurs in unipolar psychotic depression, and functional recovery often lags recovery from psychotic and depressive symptoms. Patients may find it helpful to gradually resume their normal activities following remission of the mood episode. (See
         <a class="local">
          'Functional recovery'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Johnson J, Horwath E, Weissman MM. The validity of major depression with psychotic features based on a community study. Arch Gen Psychiatry 1991; 48:1075.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marcus SC, Olfson M. National trends in the treatment for depression from 1998 to 2007. Arch Gen Psychiatry 2010; 67:1265.
          </a>
         </li>
         <li class="breakAll">
          Depression: TheTreatment and Management of Depression in Adults (Updated Edition). National Clinical Practice Guideline 90. National Institute for Health &amp; Clinical Excellence. http://guidance.nice.org.uk/CG90 (Accessed on July 18, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østergaard SD, Meyers BS, Flint AJ, et al. Measuring psychotic depression. Acta Psychiatr Scand 2014; 129:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østergaard SD, Meyers BS, Flint AJ, et al. Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account. J Affect Disord 2014; 160:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østergaard SD, Pedersen CH, Uggerby P, et al. Clinical and psychometric validation of the psychotic depression assessment scale. J Affect Disord 2015; 173:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østergaard SD, Rothschild AJ, Flint AJ, et al. Rating scales measuring the severity of psychotic depression. Acta Psychiatr Scand 2015; 132:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Østergaard SD, Rothschild AJ, Flint AJ, et al. Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS). J Affect Disord 2016; 190:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rhoades HM, Overall JE. The semistructured BPRS interview and rating guide. Psychopharmacol Bull 1988; 24:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Psychiatric Association. Practice guideline for the treatment of major depressive disorder, third edition. Am J Psychiatry 2010; 167:10.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroessler D. Relative Efficacy Rates for Therapies of Delusional Depression. Convuls Ther 1985; 1:173.
          </a>
         </li>
         <li class="breakAll">
          Rothschild AJ. Clinical Manual for Diagnosis and Treatment of Psychotic Depression, American Psychiatric Publishing, Inc., Washington, DC 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olfson M, Marcus S, Sackeim HA, et al. Use of ECT for the inpatient treatment of recurrent major depression. Am J Psychiatry 1998; 155:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoskopf C, Horn SD. Predicting length of stay for patients with psychoses. Health Serv Res 1992; 26:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson KG, Kraitberg NJ, Brown JH, Bergman JN. Electroconvulsive therapy in the treatment of depression: the impact on length of stay. Compr Psychiatry 1991; 32:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: a meta-analysis of physical treatments. J Affect Disord 1992; 24:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothschild AJ. Management of psychotic, treatment-resistant depression. Psychiatr Clin North Am 1996; 19:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyers BS, Flint AJ, Rothschild AJ, et al. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD). Arch Gen Psychiatry 2009; 66:838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothschild AJ, Williamson DJ, Tohen MF, et al. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijkstra J, Burger H, van den Broek WW, et al. Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine. Acta Psychiatr Scand 2010; 121:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Müller-Siecheneder F, Müller MJ, Hillert A, et al. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiker DG, Weiss JC, Dealy RS, et al. The pharmacological treatment of delusional depression. Am J Psychiatry 1985; 142:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim-Romo DN, Rascati KL, Richards KM, et al. Medication Adherence and Persistence in Patients with Severe Major Depressive Disorder with Psychotic Features: Antidepressant and Second-Generation Antipsychotic Therapy Versus Antidepressant Monotherapy. J Manag Care Spec Pharm 2016; 22:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord 2009; 117 Suppl 1:S26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leadholm AK, Rothschild AJ, Nolen WA, et al. The treatment of psychotic depression: is there consensus among guidelines and psychiatrists? J Affect Disord 2013; 145:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honkola J, Hookana E, Malinen S, et al. Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J 2012; 33:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijkstra J, Lijmer J, Balk FJ, et al. Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis. Br J Psychiatry 2006; 188:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farahani A, Correll CU. Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment. J Clin Psychiatry 2012; 73:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kruizinga J, Liemburg E, Burger H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2021; 12:CD004044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wijkstra J, Lijmer J, Burger H, et al. Pharmacological treatment for psychotic depression. Cochrane Database Syst Rev 2015; :CD004044.
          </a>
         </li>
         <li class="breakAll">
          FDA Executive Summary: Prepared for the January 27-28, 2011 meeting of the Neurological Devices Panel. Meeting to Discuss the Classification of Electroconvulsive Therapy Devices (ECT). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM240933.pdf (Accessed on May 25, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           UK ECT Review Group. Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 2003; 361:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kho KH, van Vreeswijk MF, Simpson S, Zwinderman AH. A meta-analysis of electroconvulsive therapy efficacy in depression. J ECT 2003; 19:139.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging, American Psychiatric Association, 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petrides G, Fink M, Husain MM, et al. ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE. J ECT 2001; 17:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nordenskjöld A, von Knorring L, Engström I. Predictors of the short-term responder rate of Electroconvulsive therapy in depressive disorders--a population based study. BMC Psychiatry 2012; 12:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumberger DM, Mulsant BH, Emeremni C, et al. Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial. J Psychiatr Res 2011; 45:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flint AJ, Rifat SL. The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT. Int J Geriatr Psychiatry 1998; 13:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Price LH, Conwell Y, Nelson JC. Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression. Am J Psychiatry 1983; 140:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Birkenhäger TK, van den Broek WW, Wijkstra J, et al. Treatment of unipolar psychotic depression: an open study of lithium addition in refractory psychotic depression. J Clin Psychopharmacol 2009; 29:513.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudiano BA, Miller IW, Herbert JD. The treatment of psychotic major depression: is there a role for adjunctive psychotherapy? Psychother Psychosom 2007; 76:271.
          </a>
         </li>
         <li class="breakAll">
          Bach P, Guadiano BA, Pankey J, et al. Acceptance, mindfulness values and psychosis: Applying Acceptance and Commitment Therapy (ACT) to the chronically mentally ill. In: Mindfulness-Based Treatment Approaches: Clinician’s Guide to Evidence Base and Applications, Baer RA (Ed), Academic Press, 2006. p.93.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaudiano BA, Nowlan K, Brown LA, et al. An open trial of a new acceptance-based behavioral treatment for major depression with psychotic features. Behav Modif 2013; 37:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coryell W, Keller M, Lavori P, Endicott J. Affective syndromes, psychotic features, and prognosis. I. Depression. Arch Gen Psychiatry 1990; 47:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Strakowski SM, Zarate C Jr, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry 2000; 48:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tohen M, Hennen J, Zarate CM Jr, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry 2000; 157:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coryell W, Leon A, Winokur G, et al. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry 1996; 153:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murphy E. The prognosis of depression in old age. Br J Psychiatry 1983; 142:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rothschild AJ, Schatzberg AF. Psychotic Depression: A newly recognized subtype. Clin Neurosci 1993; 1:75.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16546 Version 26.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1845225" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The validity of major depression with psychotic features based on a community study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1845225" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The validity of major depression with psychotic features based on a community study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21135326" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : National trends in the treatment for depression from 1998 to 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21135326" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : National trends in the treatment for depression from 1998 to 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23799875" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Measuring psychotic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24439830" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Measuring treatment response in psychotic depression: the Psychotic Depression Assessment Scale (PDAS) takes both depressive and psychotic symptoms into account.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25462426" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Clinical and psychometric validation of the psychotic depression assessment scale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26016647" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Rating scales measuring the severity of psychotic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26496016" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Establishing the cut-off score for remission and severity-ranges on the Psychotic Depression Assessment Scale (PDAS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14399272" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : A rating scale for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3290934" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The semistructured BPRS interview and rating guide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Practice guideline for the treatment of major depressive disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Practice guideline for the treatment of major depressive disorder, third edition
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11940821" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Relative Efficacy Rates for Therapies of Delusional Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11940821" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Relative Efficacy Rates for Therapies of Delusional Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9433334" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Use of ECT for the inpatient treatment of recurrent major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1737707" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Predicting length of stay for patients with psychoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1935025" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Electroconvulsive therapy in the treatment of depression: the impact on length of stay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1347545" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Psychotic (delusional) depression: a meta-analysis of physical treatments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8827188" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Management of psychotic, treatment-resistant depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19652123" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15232326" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19694628" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Treatment of unipolar psychotic depression: a randomized, double-blind study comparing imipramine, venlafaxine, and venlafaxine plus quetiapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9555596" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3883815" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The pharmacological treatment of delusional depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27123919" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Medication Adherence and Persistence in Patients with Severe Major Depressive Disorder with Psychotic Features: Antidepressant and Second-Generation Antipsychotic Therapy Versus Antidepressant Monotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19674794" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23021823" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The treatment of psychotic depression: is there consensus among guidelines and psychiatrists?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21920969" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Psychotropic medications and the risk of sudden cardiac death during an acute coronary event.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16648526" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pharmacological treatment for unipolar psychotic depression: Systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22579147" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34875106" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pharmacological treatment for psychotic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26225902" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Pharmacological treatment for psychotic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26225902" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Pharmacological treatment for psychotic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12642045" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12972983" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : A meta-analysis of electroconvulsive therapy efficacy in depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12972983" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A meta-analysis of electroconvulsive therapy efficacy in depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11731725" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22900754" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Predictors of the short-term responder rate of Electroconvulsive therapy in depressive disorders--a population based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21300377" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9489577" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The treatment of psychotic depression in later life: a comparison of pharmacotherapy and ECT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6131612" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19745662" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Treatment of unipolar psychotic depression: an open study of lithium addition in refractory psychotic depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17700047" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The treatment of psychotic major depression: is there a role for adjunctive psychotherapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17700047" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The treatment of psychotic major depression: is there a role for adjunctive psychotherapy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23223385" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : An open trial of a new acceptance-based behavioral treatment for major depression with psychotic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2360858" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Affective syndromes, psychotic features, and prognosis. I. Depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11018220" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10671390" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8599395" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Importance of psychotic features to long-term course in major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6839065" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The prognosis of depression in old age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Psychotic Depression: A newly recognized subtype
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
